|[May 08, 2014]
Research and Markets: Nasopharyngeal Cancer - Pipeline Review, H1 2014: 6 Companies and 17 Drugs Profiled
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/jqfqjc/nasopharyngeal)
has announced the addition of the "Nasopharyngeal
Cancer - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic
development for Nasopharyngeal Cancer, complete with comparative
analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for
Nasopharyngeal Cancer and special features on late-stage and
The report features investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from proprietary daabases,
Company/University websites, SEC (News - Alert) filings, investor presentations and
featured press releases from company/university sites and
industry-specific third party sources.
Drug profiles/records featured in the report undergoes periodic updation
following a stringent set of processes that ensures that all the
profiles are updated with the latest set of information. Additionally,
processes including live news & deals tracking, browser based alert-box
and clinical trials registries tracking ensure that the most recent
developments are captured on a real time basis.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Merck & Co., Inc.
Astex Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals Inc.
National Cancer Centre Singapore
Autologous Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes +
Modified Vaccinia Ankara Vaccine
Cytokine-Induced Killer Cells + [cisplatin] + [gemcitabine]
Icotinib + [cisplatin] + [paclitaxel] + Radiation Therapy
LMP Specific Cytotoxic T-Lymphocytes
HLA Matched Allogeneic Virus Specific Cytotoxic T Lymphocytes
EBV-Specific CTL Therapy
Therapeutic p53 Gene Agent
LMP2-TCR Gene Therapy
For more information visit http://www.researchandmarkets.com/research/jqfqjc/nasopharyngeal
[ InfoTech Spotlight's Homepage ]